ALSO NOTED: Xenova agrees to buyout; Genentech boosting manufacturing; Pfizer expands research lab; and much more...

> UK-based Xenova has agreed to be acquired by the newly formed Celtic Group. Story

> Expecting to see a big demand for its therapies, Genentech is boosting its manufacturing abilities to nearly full capacity. Article

> Pfizer is expanding its research lab in Cambridge, Massachusetts. Story

> Pfizer is also planning a $5 billion stock buyback. Story

> ODC Therapy has received the OK to expand clinical trials into a cancer vaccine. Report

And Finally... The Rehabilitation Institute of Chicago is developing a prosthetic limb that restores a sense of touch. Story

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.